Loading...
XNYS
IGC
Market cap15mUSD
Jul 09, Last price  
0.28USD
1D
1.42%
1Q
-7.59%
Jan 2017
-0.36%
IPO
-99.51%
Name

IGC Pharma Inc

Chart & Performance

D1W1MN
XNYS:IGC chart
P/E
—
P/S
12.49
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.76%
Rev. gr., 5y
5.72%
Revenues
1m
-6.69%
-765,0002,188,00035,339,00017,898,0004,074,0004,200,0008,030,0002,273,0007,680,0006,367,000580,3722,193,0005,116,0004,072,000898,000397,000911,0001,345,0001,271,0001,186,000
Net income
-7m
L-8.05%
1,518,000-5,215,000-522,000-4,789,000-20,241,000-7,752,000-2,252,000-3,023,000-4,614,000-2,808,000-1,867,000-1,786,000-4,097,000-7,315,000-8,811,000-15,016,000-11,506,000-13,000,000-7,121,000-6,548,000
CFO
-6m
L+23.94%
-1,558,559-8,569,000-8,113,641-2,955,461-2,634,736-5,022,362178,199-1,742,054-2,583,642-157,702-1,391,077-1,931,078-3,330,000-8,677,000-10,800,000-7,462,000-7,047,000-5,199,000-4,795,000-5,942,999

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
URL
https://igcpharma.com/
IPO date
Apr 13, 2006
Employees
61
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT